A Phase 3 interventional study of AMG 162 in Low Bone Mineral Density, sponsored by Amgen. Completed. Open to female participants. Per ClinicalTrials.gov, last updated 2017-08-01.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing denosumab in Bone Diseases, Metabolic — 1 open to participants now, 1 under way, none of them phase 3. Denosumab · Bone Diseases, Metabolic.
Among the 25 studies testing denosumab in Bone Diseases, Metabolic, this one is the 11th largest by enrollment, is one of 2 that started in 2006, is one of 13 in phase 3, and was the 4th registered.
663 studies on the registry are indexed under Bone Diseases, Metabolic; 95 are open to participants now.
Browse Bone Diseases, Metabolic studies →1 of the 25 studies testing denosumab in Bone Diseases, Metabolic is open now, in 1 country. Recruiting first, the newest first:
Capital Medical University · Sites in China
Ages 18–100
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 14 · Phase 4 4
First in 2002; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 60 across 510 interventional studies indexed under Bone Diseases, Metabolic.
Median enrollment 100 across the 25 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 25 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
23 studies in Bone Diseases, Metabolic by Amgen: none open now, none under way, none of them phase 3. Of 23 finished, 21 (91%) have results posted.
Among the 23 studies in Bone Diseases, Metabolic by Amgen, this one is the 13th largest by enrollment, is one of 3 that started in 2006, is one of 12 in phase 3, and was the 4th registered.
Amgen’s Bone Diseases, Metabolic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing denosumab in Bone Diseases, Metabolic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 23 in Bone Diseases, Metabolic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women with Low Bone Mineral Density
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
Drug: AMG 162
AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
Lumbar Spine Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8
Time frame: 8 years
Total Hip Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8
Time frame: 8 years
Distal 1/3 Radius Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8
Time frame: 8 years
Bone-Specific Alkaline Phosphatase Percent Change From Parent Study 20010223 Baseline to Year 8
Time frame: 8 years
Serum C-Telopeptide Percent Change From Parent Study 20010223 Baseline to Year 8
Time frame: 8 years
Subjects who successfully completed the double-blind, randomized, 4-year dose-ranging parent study 20010223
| Milestone | Placebo | Denosumab 210 mg Q6M | Denosumab 30 mg Q3M | Denosumab Continuous Treatment | Alendronate 70mg QW |
|---|---|---|---|---|---|
| Started | 23 | 17 | 14 | 124 | 22 |
| Completed | 12 | 12 | 10 | 90 | 14 |
| Not completed | 11 | 5 | 4 | 34 | 8 |
| Withdrew: Adverse event | 1 | 1 | 0 | 5 | 1 |
| Withdrew: Death | 2 | 0 | 2 | 4 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 2 | 2 |
| Withdrew: Physician decision | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 0 | 14 | 4 |
| Withdrew: Site closure etc | 4 | 2 | 1 | 8 | 1 |
| percent | Placebo | Denosumab 210 mg Q6M | Denosumab 30 mg Q3M | Denosumab Continuous Treatment | Alendronate 70mg QW |
|---|---|---|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8 | 8.4 (4.4 to 12.4) | 11.2 (7.2 to 15.2) | 11.0 (6.0 to 16.0) | 16.5 (14.9 to 18.1) | 12.4 (8.5 to 16.4) |
| percent | Placebo | Denosumab 210 mg Q6M | Denosumab 30 mg Q3M | Denosumab Continuous Treatment | Alendronate 70mg QW |
|---|---|---|---|---|---|
| Bone-Specific Alkaline Phosphatase Percent Change From Parent Study 20010223 Baseline to Year 8 | -55.8 (-66.7 to -24.4) | -44.7 (-63.6 to -23.8) | -52.5 (-60.4 to -27.1) | -44.4 (-61.9 to -10.2) | -54.2 (-65.1 to -24.9) |
| percent | Placebo | Denosumab 210 mg Q6M | Denosumab 30 mg Q3M | Denosumab Continuous Treatment | Alendronate 70mg QW |
|---|---|---|---|---|---|
| Total Hip Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8 | 1.1 (-1.2 to 3.5) | 4.3 (2.0 to 6.6) | 2.3 (-0.5 to 5.1) | 6.8 (5.8 to 7.7) | 3.4 (1.1 to 5.7) |
| percent | Placebo | Denosumab 210 mg Q6M | Denosumab 30 mg Q3M | Denosumab Continuous Treatment | Alendronate 70mg QW |
|---|---|---|---|---|---|
| Distal 1/3 Radius Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8 | -5.2 (-7.4 to -2.9) | 1.4 (-0.9 to 3.8) | 0.6 (-1.9 to 3.1) | 1.3 (0.5 to 2.2) | -2.2 (-4.3 to -0.1) |
| percent | Placebo | Denosumab 210 mg Q6M | Denosumab 30 mg Q3M | Denosumab Continuous Treatment | Alendronate 70mg QW |
|---|---|---|---|---|---|
| Serum C-Telopeptide Percent Change From Parent Study 20010223 Baseline to Year 8 | -66.4 (-90.8 to -27.3) | -72.0 (-84.9 to -57.4) | -48.0 (-87.9 to 26.8) | -64.6 (-77.3 to -2.7) | -49.8 (-82.0 to -45.4) |
Collected over 48 months (i.e., 4 years during the 20050233 extension study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 3/23 (13%) | 18/23 (78.3%) |
| Denosumab 210 mg Q6M | — | 3/17 (17.6%) | 15/17 (88.2%) |
| Denosumab 30 mg Q3M | — | 5/14 (35.7%) | 13/14 (92.9%) |
| Denosumab Continuous Treatment | — | 31/124 (25%) | 106/124 (85.5%) |
| Alendronate 70 mg QW | — | 3/22 (13.6%) | 19/22 (86.4%) |
| All Participants | — | 45/200 (22.5%) | 171/200 (85.5%) |
| Event | Placebo | Denosumab 210 mg Q6M | Denosumab 30 mg Q3M | Denosumab Continuous Treatment | Alendronate 70 mg QW | All Participants |
|---|---|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/23 | 1/17 | 3/14 | 0/124 | 0/22 | 4/200 |
| Hypochromic anaemiaBlood and lymphatic system disorders | 0/23 | 0/17 | 1/14 | 0/124 | 0/22 | 1/200 |
| Angina unstableCardiac disorders | 0/23 | 0/17 | 1/14 | 0/124 | 0/22 | 1/200 |
| Coronary artery diseaseCardiac disorders | 0/23 | 0/17 | 1/14 | 1/124 | 0/22 | 2/200 |
| Coronary artery stenosisCardiac disorders | 0/23 | 0/17 | 1/14 | 0/124 | 0/22 | 1/200 |
| Colonic stenosisGastrointestinal disorders | 0/23 | 0/17 | 1/14 | 0/124 | 0/22 | 1/200 |
| DeathGeneral disorders | 0/23 | 0/17 | 1/14 | 0/124 | 0/22 | 1/200 |
| PneumoniaInfections and infestations | 0/23 | 0/17 | 1/14 | 2/124 | 0/22 | 3/200 |
| Fibula fractureInjury, poisoning and procedural complications | 0/23 | 0/17 | 1/14 | 0/124 | 0/22 | 1/200 |
| Traumatic brain injuryInjury, poisoning and procedural complications | 0/23 | 0/17 | 1/14 | 0/124 | 0/22 | 1/200 |
| Event | Placebo | Denosumab 210 mg Q6M | Denosumab 30 mg Q3M | Denosumab Continuous Treatment | Alendronate 70 mg QW | All Participants |
|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 9/23 | 7/17 | 2/14 | 24/124 | 3/22 | 45/200 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/23 | 4/17 | 4/14 | 20/124 | 5/22 | 37/200 |
| HypertensionVascular disorders | 2/23 | 3/17 | 4/14 | 13/124 | 3/22 | 25/200 |
| BronchitisInfections and infestations | 2/23 | 4/17 | 3/14 | 7/124 | 1/22 | 17/200 |
| Back painMusculoskeletal and connective tissue disorders | 3/23 | 4/17 | 1/14 | 14/124 | 3/22 | 25/200 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/23 | 4/17 | 0/14 | 14/124 | 3/22 | 23/200 |
| Procedural painInjury, poisoning and procedural complications | 2/23 | 0/17 | 3/14 | 7/124 | 3/22 | 15/200 |
| DepressionPsychiatric disorders | 3/23 | 3/17 | 0/14 | 6/124 | 2/22 | 14/200 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 4/23 | 0/17 | 1/14 | 7/124 | 1/22 | 13/200 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 4/23 | 0/17 | 1/14 | 9/124 | 0/22 | 14/200 |
| Age, Continuous(Years) | Placebo | Denosumab 210 mg Q6M | Denosumab 30 mg Q3M | Denosumab Continuous Treatment | Alendronate 70mg QW | Total |
|---|---|---|---|---|---|---|
| Mean | 65.8 ± 9.1 | 65.8 ± 9.4 | 68.0 ± 7.2 | 65.8 ± 7.0 | 66.6 ± 8.9 | 66.1 ± 7.7 |
| Sex: Female, Male(Participants) | Placebo | Denosumab 210 mg Q6M | Denosumab 30 mg Q3M | Denosumab Continuous Treatment | Alendronate 70mg QW | Total |
|---|---|---|---|---|---|---|
| Female | 23 | 17 | 14 | 124 | 22 | 200 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Denosumab 210 mg Q6M | Denosumab 30 mg Q3M | Denosumab Continuous Treatment | Alendronate 70mg QW | Total |
|---|---|---|---|---|---|---|
| White or Caucasian | 18 | 16 | 12 | 112 | 20 | 178 |
| Black or African American | 0 | 0 | 1 | 2 | 0 | 3 |
| Hispanic or Latino | 5 | 1 | 1 | 8 | 2 | 17 |
| Asian | 0 | 0 | 0 | 1 | 0 | 1 |
| Japanese | 0 | 0 | 0 | 1 | 0 | 1 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Aborigine | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline Bone Mineral Density T-score of Each Anatomic Site(T-score) | Placebo | Denosumab 210 mg Q6M | Denosumab 30 mg Q3M | Denosumab Continuous Treatment | Alendronate 70mg QW | Total |
|---|---|---|---|---|---|---|
| Lumbar spine BMD T-score | -2.36 ± 0.62 | -2.02 ± 1.16 | -1.29 ± 0.94 | -1.35 ± 0.87 | -1.64 ± 1.09 | -1.55 ± 0.96 |
| Total hip BMD T-score | -1.63 ± 0.75 | -1.39 ± 0.67 | -1.05 ± 0.75 | -1.08 ± 0.68 | -1.50 ± 0.81 | -1.21 ± 0.73 |
| Distal 1/3 radius T-score | -1.91 ± 1.25 | -1.45 ± 0.98 | -1.14 ± 1.29 | -1.23 ± 1.21 | -1.57 ± 0.98 | -1.35 ± 1.19 |
No study locations are listed for this record.
Ran from May 2006 to primary completion in Mar 2011, 58 months.
Results were first posted in Jul 2013, 2 years 4 months after primary completion.
Of 26 phase 3 interventional studies under Bone Diseases, Metabolic, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 57. This study's 58 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab